Recently published evidence from two large-scale clinical trials conducted in England and in Denmark suggests that faecal occult blood screening for colorectal cancer significantly reduces mortality. However, before screening can be advocated as part of national health policy, its cost-effectiveness
Costs of screening for colorectal cancer: An Australian programme
โ Scribed by Jeff Gow
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 68 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1057-9230
No coin nor oath required. For personal study only.
โฆ Synopsis
The total costs (direct and indirect) associated with the operation of an Australian community based screening programme for colorectal cancer (CRC) were estimated. One-year costs of the programme were estimated to be AUS$1 347 948 to screen 24 000 participants. This corresponded to AUS$8868 per polyp and AUS$28 679 per cancer detected. The results presented here are quite favourable compared with the only other Australian screening programme that has reported costs. That programme estimated a cost per cancer detected of AUS$24 233 (adjusted). The recent Australian public health literature has been almost unanimously against recommending the operation of population based CRC screening programmes. More recently, overseas randomized control trials have reported reduced mortality (15 to 33%) as a result of these programmes. Cost data, as presented here combined with the epidemiological evidence, indicate the challenge the Federal Government is now confronted with in formulating policy to control the increasing number of deaths from the disease.
๐ SIMILAR VOLUMES
## Background: It has been estimated that the prevalence of carriers of a mutated mismatch repair (mmr) gene among the general population in western countries is between 5 and 50 per 10,000. these carriers have a risk of >85% of developing colorectal carcinoma (crc) and therefore need careful follo
## BACKGROUND. Although the efficacy of mass screening for colorectal carcinoma (CRC) with a fecal occult blood test has been demonstrated in several randomized trials, a mass screening approach used in countries with intermediate or low incidence of CRC might be costly. Screening high risk people
## Background: A consensus meeting on screening and global strategy for prostate carcinoma, held in antwerp in 1994, determined the willingness among european cancer prevention centers to pursue vigorously the collaborative formation of a multinational randomized screening trial. this trial was to
Variance estimators are derived for estimators of the average lead time and average benefit time due to screening in a randomized screening trial via influence functions. The influence functions demonstrate that these estimators are asymptotically equivalent to the mean difference, between the study